LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

DexCom Inc

Затворен

СекторЗдравеопазване

69.73 1.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

68.85

Максимум

71.01

Ключови измерители

By Trading Economics

Приходи

-68M

200M

Продажби

-68M

1.2B

P/E

Средно за сектора

29.644

50.958

EPS

0.56

Марж на печалбата

16.738

Служители

11,000

EBITDA

-52M

337M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+19.86% upside

Дивиденти

By Acuity

Следващи печалби

29.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3B

27B

Предишно отваряне

68.54

Предишно затваряне

69.73

Настроения в новините

By Acuity

18%

82%

35 / 342 Класиране в Healthcare

DexCom Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Относно DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat